Substance-induced psychosis (SIP) presents diagnostic challenges in distinguishing it from primary psychotic disorders, with substance timing, symptom type, and duration being key differentiators. Effective treatment combines antipsychotic medications and substance cessation strategies. Dr. Athanasiou reviews key points in the management of SIP.

Many states have passed laws allowing the prescription of cannabis as a treatment for PTSD in spite of the absence of high-quality evidence. In this prospective, double-blinded trial, researchers failed to find evidence that either THC or CBD is an effective treatment for PTSD.

Older adults with substance use disorders present to clinicians in various stages of change. Dr. Bogunovic discusses brief clinical interventions including motivational interviewing and how to approach harm reduction.

How do you choose a screening tool for substance use disorders in older adults, and what do you do when a patient screens positive? We discuss common screening tools, assessments, and interventions based on an older adult’s risk level.

In recent years, cannabis with widely varying THC concentrations has become available. But is there a link between how much THC a cannabis product contains and its risk of adverse effects. Researchers here add to the mounting evidence that the answer is likely yes.

Naltrexone was once hailed as a treatment for all addictive disorders. While the hype has not entirely panned out, it still holds an important place in our armamentarium of addiction treatments. Here, we review the evidence for its use and provide prescribing recommendations.